Completed PHASE2 INTERVENTIONAL NCT00073502

Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer

A Phase II Study of Single Agent OSI-7904L In Patients With Locally Advanced or Metastatic Adenocarcinoma Of the Stomach or Gastroesophageal Junction

Sponsor: OSI Pharmaceuticals

Conditions Gastric Adenocarcinoma Gastroesophageal Adenocarcinoma

Interventions OSI-7904L

Updated 5 times since 2017 Last updated: Feb 17, 2006 Started: Oct 31, 2003 Completion: Oct 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00073502, this PHASE2 trial focuses on Gastric Adenocarcinoma and Gastroesophageal Adenocarcinoma and remains completed. Sponsored by OSI Pharmaceuticals, it has been updated 5 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

OSI Pharmaceuticals

Data source: OSI Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

B-3000 Leuven, Belgium , Belfast, United Kingdom , Bristol, United Kingdom , Glasgow, United Kingdom , Houston, United States , Leeds, United Kingdom , Manchester, United Kingdom , Oxford, United Kingdom , Philadelphia, United States , Salt Lake City, United States and 1 more location